secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001558370-25-010031
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia partners with Syntekabio to use AI for new DA-1241 indications
----------------------------------------------------------------------

- Collaboration leverages Syntekabio’s DeepMatcher platform to screen >1,700 protein targets for new DA-1241 indications.
- Follows positive Phase 2a data in MASH; DA-1241 showed safety, hepatoprotective, and glucose-regulating effects.
- No financial terms disclosed; initial insights expected later in 2025.
- DA-1241 is a novel oral GPR119 agonist in clinical development for cardiometabolic diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025010031/0001558370-25-010031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025010031/mtva-20250804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer